Gap junctions, the channels formed by the connexin (Cx) family of proteins, are responsible for direct intercellular communication. Although connexins are considered as tumor suppressors, their overall role in cancer onset, progression and metastasis is somewhat controversial. This study uses a novel Cx43 mutant mouse model (G60S mice) and cross-breeding strategies to determine the role of Cx43 in all stages of breast tumorigenesis. G60S mice were cross-bred with ErbB2 overexpressing mice, and spontaneous and 7,12-dimethylbenz[a]anthracene (DMBA)-induced tumor development was evaluated. Mice were killed when tumors reached B1 cm 3 or when mice showed signs of critical illness. In both spontaneous and DMBA studies, onset of palpable tumors was delayed in G60S mice compared with mice in control groups. Moreover, while tumors from control mice reached the size threshold, most DMBA-exposed Cx43 mutant mice were killed prematurely because of labored breathing, independent of the presence of a palpable tumor. Reduced Cx43 levels in Cx43 mutant mice were accompanied by extensive mammary gland hyperplasia. Lung histology revealed that all Cx43 mutant mice exhibited mammaglobin-positive mammary gland metastases to the lung, and the number of metastases was increased by threefold in Cx43 mutant mice on treatment with DMBA. Thus, while reduced levels of Cx43 delayed the onset of palpable tumors, normal Cx43 levels inhibited mammary gland tumor metastasis to the lungs. Understanding the mechanisms of how Cx43, which is expressed primarily in myoepithelial cells, inhibits mammary gland tumor metastasis is critical as Cx43 is assessed as a candidate for therapeutic intervention.
Introduction
Metastatic breast cancer remains essentially incurable, highlighting the critical need for new therapeutic targets and treatment paradigms. For many years, several different experimental in vivo procedures have been used to investigate breast cancer progression. In many mouse models, tumorigenesis is initiated by exposing wild-type or genetically modified mice to a carcinogen. 7,12-Dimethylbenz [a] anthracene (DMBA) is one of the most common carcinogens used, and this treatment often causes cell transformation in the mammary gland that progresses to metastatic disease in distant tissues such as lung (Medina, 2007) . In other mouse models of tumor onset and progression, genetically modified mice are engineered to overexpress an oncogene or to harbor a loss-of-function mutation in a key tumor suppressor gene, leading to increased incidence of tumorigenesis. For example, mice overexpressing a mouse mammary tumor virus (MMTV)-driven rat neu (ErbB2) gene (an oncogene overexpressed in B30% of breast cancer patients) have been used extensively to mimic a subset of human breast cancers (Guy et al., 1992) . ErbB2 overexpressing mice have been shown to develop spontaneous mammary gland tumors within B30 weeks and these tumors readily metastasize to the lungs (Guy et al., 1992) . To further increase their versatility, ErbB2 overexpressing mice can be cross-bred with other genetically modified mice to examine molecular mechanisms that may enhance or inhibit tumorigenesis (Hewitt et al., 2002; Jacquemart et al., 2009) .
The mammary gland epithelium is composed of two layers of cells, an inner layer of luminal epithelial cells and an outer layer of myoepithelial cells, surrounded by a basement membrane. The epithelium develops during puberty, under the influence of hormones, a process thought to require extensive interactions between myoepithelial and luminal cells, but also between the epithelium and the surrounding stroma (Pitelka et al., 1973; Sternlicht, 2006) . Myoepithelial cells are necessary for the development and function of the luminal cell layer, as paracrine regulation and junctional attachments allow for cross-talk within the epithelium (Pitelka et al., 1973; Adriance et al., 2005) . As breast cancer typically arises from the luminal layer, with the rare exception of myoepithelioma (Foschini and Eusebi, 1998) , the role of myoepithelial cells in tumorigenesis has not been acutely studied. Recently, myoepithelial cells have received more attention as they have been suggested as a 'natural tumor suppressor' Gudjonsson et al., 2005) . Indeed, through their strategic localization between the luminal cells and the surrounding stroma, it has been suggested that myoepithelial cells facilitate the polarity of the epithelium and function as a physical barrier against loss of growth control, tumor cell invasion and angiogenesis (Barsky and Karlin, 2005) .
Gap junctions are intercellular channels assembled from a family of transmembrane protein called connexins (Cxs). They allow the bidirectional passage of ions, metabolites and secondary messengers in a process known as gap junctional intercellular communication (GJIC) (Mese et al., 2007) . GJIC has been implicated in the regulation of homeostasis and a diverse array of cellular functions related to cell specialization, growth and differentiation (Herve et al., 2007) . In the mouse, gap junctions composed of Cx26, Cx30 or Cx32 have been identified between mammary luminal cells, whereas Cx43 gap junctions were found to be more restricted to myoepithelial cells and stromal fibroblasts (El-Sabban et al., 2003) . Similarly, in human breast epithelium, Cx26 has been localized to luminal cells, whereas Cx43 is mainly present between myoepithelial cells, but has been reported to be expressed in luminal cells as well (Monaghan et al., 1996; Laird et al., 1999) . Although connexins were first proposed as tumor suppressors more than two decades ago (Lee et al., 1991 (Lee et al., , 1992 , their role in breast cancer is still poorly understood and somewhat controversial. Several studies examining primary breast tumor biopsy samples from patients have reported either a downregulation of Cx26 and Cx43 or mis-localization of these connexins to intracellular compartments (Lee et al., 1991 (Lee et al., , 1992 Laird et al., 1999; Kanczuga-Koda et al., 2006) . Consistently, it has been shown that re-expression of connexins in breast tumor cell lines can result in a partial cell re-differentiation to a more normal phenotype (Hirschi et al., 1996; Kalra et al., 2006; McLachlan et al., 2007) , whereas downregulation of connexins in breast cell lines render them more migratory and invasive . However, a few studies have also reported an upregulation of connexins in breast cancer (Jamieson et al., 1998; Kanczuga-Koda et al., 2006; Naoi et al., 2007) . Finally, it has been suggested that the role of connexins may differ depending of the type of tumor or its stage of progression, even favouring metastasis (McLachlan et al., 2007; Naus and Laird, 2010) . Together, these studies reflect the need for an appropriate mouse model to study the role of connexins at all stages of mammary gland tumorigenesis.
In 2005, a mouse model of oculodentodigital dysplasia, a human disease linked to over 62 mutations in the Cx43 gene, was generated through an N-ethyl-Nnitrosourea screening for dominant mutations (Flenniken et al., 2005; Paznekas et al., 2009) . These mice, designated as Gja1
Jrt/ þ or G60S mice, are autosomal dominant with the G60S mutant encoded on one allele. The mutant harboring mice were found to have a Cx43 trafficking defect and a substantial reduction in Cx43 protein levels in many tissues, including the mammary gland. These defects result in a decreased number of gap junction plaques and GJIC (Flenniken et al., 2005; Manias et al., 2008; Plante and Laird, 2008) . When expressed in a variety of cell types, a population of the G60S mutant can reach the plasma membrane but assembles into gap junction-like structures with greatly impaired function (Flenniken et al., 2005; McLachlan et al., 2005) . In essence, the Cx43 G60S mutant is functionally dead and furthermore has a dominantnegative effect on coexpressed wild-type Cx43 found in the G60S mice (Flenniken et al., 2005) . We previously showed that reduced Cx43 protein levels in G60S female mice are linked to delayed mammary gland development during puberty, as well as decreased milk secretion and ejection (Plante and Laird, 2008; Plante et al., 2010) . However, the consequences of mice harboring a functionally impaired form of Cx43 on breast cancer onset, progression and metastasis are still unknown.
This study aimed to determine whether the G60S mutant would render mice more susceptible to mammary gland tumor formation and whether tumors would be more aggressive. To this end, G60S mice were crossbred with ErbB2 overexpressing mice to promote mammary gland-specific tumor formation, and both spontaneous and DMBA-induced mammary gland tumorigenesis and metastasis were assessed.
Results
Mice harboring the G60S mutant have a delayed onset of palpable tumors in the mammary gland To study the effects of a Cx43 mutant on mammary gland tumorigenesis, we cross-bred male Gja1
Jrt/ þ mice, harboring a G60S mutation within the Cx43 gene, with female ErbB2 mice, overexpressing a rat ErbB2 (Neu) gene under an MMTV promoter (FVB/N-Tg (MMTVneu)202Mul/J), or with FVB control females. The resulting phenotypes were designated WT-FVB (wild-type Cx43 and no ErbB2 overexpression), WT-ErbB2 (wild-type Cx43 and heterozygous for ErbB2 overexpression), G60S-FVB (harboring the G60S mutant and no ErbB2 overexpression) and G60S-ErbB2 (harboring the G60S mutant and heterozygous for ErbB2 overexpression). Surprisingly, a significant number of the resulting offspring, especially mice expressing both the mutant Cx43 and ErbB2, died before the end of the experiment (Supplementary Table S1 ). Although DMBA exposure didn't seem to affect the health of the mice based on body weight assessments during the treatment time (data not shown), the percentage of mouse deaths was even higher when mice were exposed to DMBA (Supplementary Table S1 ). Mice killed or found dead before week 42 because of mammary gland cancer-unrelated diseases were removed from the experiment and data analysis. The remaining mice were assessed for mammary gland tumor formation and were killed either when the biggest tumors reached B1 cm 3 or when they showed signs of critical illness.
To assess whether mice harboring the G60S mutant were more or less susceptible to tumor formation, two protocols were used. First, spontaneous tumor development was assessed in the two groups of mice overexpressing ErbB2 (designated as 'spontaneous'; WT-ErbB2 and G60S-ErbB2) by palpation. Second, mice (WT-FVB, WT-ErbB2, G60S-FVB and G60S-ErbB2) were treated with either oil or DMBA and then assessed for palpable tumors weekly. Tumors were first detected at B40 weeks in spontaneous WT-ErbB2 mice, with 50% of the mice exhibiting palpable tumors by B72 weeks (Figure 1a) . Surprisingly, only one G60S-ErbB2 mouse ever developed a palpable spontaneous tumor (Figure 1a ). In the DMBA-treated groups, the onset of palpable tumors in WT-ErbB2 and WT-FVB mice was B20-weeks earlier with 50% of the mice exhibiting tumors at 32 and 36 weeks of age, respectively (Figure 1b) . In G60S mice exposed to DMBA, tumor formation was delayed compared with DMBA-treated WT groups, with the first tumors being detected between weeks 30 and 35 (Figure 1b) . However, G60S mice typically had to be killed before week 42 because of labored breathing, independent of the presence of a mammary gland tumor. Collectively, only one oil-treated WT-ErbB2 mouse formed a palpable tumor (data not shown). Together, these results suggest that exposure to DMBA reduces tumor latency in all strains and that mice harboring the G60S mutant have delayed palpable mammary gland tumor onset.
WT mice have multiple and larger tumors compared with G60S mice At the time of killing, all mouse mammary gland tumors were counted and measured. Approximately 70% of spontaneous WT-ErbB2 mice developed at least one tumor by the age of 87 weeks ( Figure 1c) . Surprisingly, only one G60S-ErbB2 mouse ever formed a spontaneous tumor. In DMBA-treated animals, over 80% of WT-FVB and WT-ErbB2 mice formed at least one Size and growth rate were evaluated from all groups. In all, 22 tumors in the spontaneous WT-ErbB2 mice group, but only 1 tumor in the G60S-ErbB2 mice group, were palpated and evaluated. For DMBA, N ¼ 15 for WT-FVB; N ¼ 9 for G60S-FVB; N ¼ 17 for WT-ErbB2; N ¼ 10 for G60S-ErbB2. (d, g) Graphs represent the average size of the biggest tumor at the time of killing mice (mean ± s.e.m.). *Po0.05; ***Po0.001. (e, h) Graphs represent the average growth rate of the biggest tumors (mean ± s.e.m.). Growth rates were obtained by dividing the size of the biggest tumor at the time of killing by the number of days since the tumor was first palpated. *Po0.05.
Cx43 inhibits mammary gland tumor metastasis to the lung I Plante et al tumor, compared with B45% of the G60S-FVB and B60% of the G60S-ErbB2 mice ( Figure 1f ). Although between B30-53% of both spontaneous WT-ErbB2 mice and DMBA-treated WT mice had multiple tumors, only one DMBA-treated G60S-ErbB2 mouse developed three tumors (Figures 1c and f) , indicating that not only the incidence of tumor formation is lower in Cx43 mutant mice, but also that these mice rarely have multiple tumors.
In keeping with our approved animal protocol, mice were killed when the largest tumor reached B1 cm 3 or when they showed signs of critical illness. In all cases, both spontaneous and DMBA-treated WT mice could reach the maximum tumor burden (Figures 1d and g ). However, G60S mutant mice bearing a palpable tumor rapidly exhibited discomfort and/or labored breathing and thus had to be killed before reaching the maximum tumor burden, resulting in an average tumor size of o0.5 cm 3 (Figures 1d and g ). In all cases, the tumor growth rate was calculated by dividing the size of the tumors at death by the number of days since the tumors were first palpated. For WT mice, the average growth rate was similar for both spontaneous and DMBA-induced tumors, ranging from 38 to 60 mm 3 per day (Figures 1e and h ). Although the growth rate did not differ between G60S-FVB and G60S-ErbB2 mice exposed to DMBA, it was significantly lower in G60S-ErbB2 mice compared with WT-ErbB2 mice ( Figure 1h ). Only one G60S-ErbB2 mouse developed a spontaneous palpable tumor (Figures 1c-e) , and both the size and the growth rate of that tumor was similar to those from DMBA-exposed G60S mice (Figures 1d, e, g and h) . Together, these results suggest that Cx43 mutant mice are rapidly affected by the presence of tumors, and had to be killed before the tumors reached the maximum size threshold.
G60S mice have hyperplasic mammary glands
To assess the architecture and tumor status in the mammary gland, we performed histological analyses. In the spontaneous groups, most of the mammary glands Figure 2 Mammary glands from Cx43 mutant mice typically become hyperplasic. Haematoxylin and eosin staining revealed that most of the mammary gland tissue from both spontaneous WT-ErbB2 (a) and G60S-ErbB2 mice (c) seem normal, with occasional areas revealing solid tumors and hyperplasia in WT-ErbB2 mice (b) or mainly hyperplasia in G60S-ErbB2 mice (d). Similar results were observed for oil-treated animals (e-h). In DMBA-treated mice, hyperplasia and solid tumors were observed in WT mice (i, k), whereas the mammary glands from G60S mice were mainly hyperplasic (j, l). Bars, 100 mm. For all groups, NX5.
Cx43 inhibits mammary gland tumor metastasis to the lung I Plante et al were composed of adipocytes with sparse ducts (Figures 2a and c) . However, in all WT-ErbB2 mice analyzed, some areas of the glands showed either hyperplasia or solid tumor (Figure 2b) . Surprisingly, approximately 75% of G60S-ErbB2 mice also showed hyperplasic areas (Figure 2d) . Similarly, in oil-treated mice, histological analysis revealed primarily normal tissue ( Figures 2e-h) ; however, between 29-44% of WT-ErbB2, G60S-FVB and G60S-ErbB2 mice had hyperplasic tissue, as well as occasional solid tumors (Figures 2f-h, inserts) . Upon DMBA treatment, X63% of the mice in each group exhibited abnormal areas of tissue (Figures 2i-l) . Interestingly, although WT mice contained both hyperplasic and solid tumors (Figures 2i and k, inserts), G60S mice contained almost exclusively hyperplasic mammary glands (Figures 2j and l) . These results suggest that mammary glands from Cx43 mutant mice become hyperplastic, independent of the overexpression of ErbB2 or exposure to DMBA.
Levels of Cx43 are reduced in the mammary gland of G60S mice compared with WT mice, and remain unchanged upon DMBA exposure As the parental Gja1 Jrt/ þ mice are on a mixed genetic background of C3 and C57BL/6J and ErbB2 mice are on a FVB background, western blot analyses was conducted on mammary glands to determine the effect of the G60S mutant on Cx43 levels upon cross-breeding. Typically, Cx43 resolves as multiple bands with the slower migrating bands representing highly phosphorylated species of Cx43 (P), and the faster migrating band, representing un-phosphorylated or a poorly phosphorylated species of Cx43 (P 0 ) (Supplementary Figure S1A , B) (as reviewed by Solan and Lampe, 2005 and by Solan and Lampe, 2007) . Although we observed that Cx43 mRNA levels were the same in WT and mutant mice (data not shown), total Cx43 protein levels were reduced by B80% in G60S-ErbB2 mice compared with WT-ErbB2 mice, with the Cx43-P species being the most affected (Supplementary Figure S1A) . Similar results were obtained when comparing oil-treated WT-ErbB2 and G60S-ErbB2 mice (data not shown), or when comparing G60S-FVB with WT-FVB mice (Supplementary Figure S1B) , confirming that the presence of the G60S mutant reduces the Cx43 content in all mice harboring this mutant. It has been reported that DMBA treatment can increase Cx43 levels in a normal human breast cell line (De Flora et al., 2006) , raising concerns that DMBA may compensate for the reduction in total Cx43 found in G60S mutant mice. In our studies, western blot analysis revealed that DMBA alone did not significantly change the levels of Cx43 (Supplementary Figure S1C , D).
G60S mice are more susceptible to lung tumors than WT mice As the lungs are one of the primary organs for mammary gland metastasis and G60S mice typically exhibited labored breathing in later stages of the study, we examined the lungs for visible evidence of tumors upon intra-tracheal fixation. Lung tumors were infrequent in spontaneous groups, but B20% of WT-ErbB2 and G60S-ErbB2 mice had between 1 and 10 visible tumors (Figures 3a and b) . Similarly, few tumors were observed in oil-treated mice, with less than 15% of mice having one or more tumors (Figures 3c and d) . In all DMBA-treated groups, lung tumors were common as B75% of WT mice exhibited 1-10 tumors (Figure 3c) , resulting in an average of nearly 7 tumors per mouse (Figure 3d ). In G60S mutant mice, not only were 100% of the mice found to exhibit visible lungs tumors, but most mice had 415 visible lesions, (Figure 3c ) with an average of 18 tumors per mouse (Figure 3d ). These results indicate that DMBA-treated Cx43 mutant mice are more susceptible to form lung tumors than WT mice.
As G60S mutant mice are typically 50% smaller than WT mice (Plante and Laird, 2008) , and microscopic tumors were not included in the initial assessment, we used histological evaluation to determine the lung tumor burden (percentage of lung tissue area occupied by tumor). In mice from spontaneous groups, a considerable area of the lung was normal for both WT-ErbB2 and G60S-ErbB2 mice (Figure 4a ). However, 57% of the WT-ErbB2 mice had sporadic lung tumors with approximately half of these tumors occupying 420% of the lung section area (Figure 4b ). In contrast, 100% of G60S-ErbB2 mice had lung tumors with B60% of the mice having tumors occupying o20% of the lung and the remaining mice having tumors that occupied 20-50% of the lung section area (Figure 4b) . In comparing the spontaneous groups, the lungs from G60S-ErbB2 mutant mice had a similar tumor burden (that is, mean area of the lung occupied by tumor) as those taken from WT-ErbB2 mice (Figure 4c ), but mutant mice had increased incidences of lung metastases (number of mice in each group that developed lung tumors) compared with WT mice.
In oil-treated mice, over 80% of the lung tissues analyzed were tumor-free for the vast majority of genetically engineered mice (Figures 4d and e) , resulting in less than 6% lung tumor burden (Figure 4f ). Upon exposure to DMBA, more than 80% of the area of the lung tissue analyzed was still tumor-free for WT mice (Figures 4d,e) , resulting in less than 6% lung tumor burden (Figure 4f ). However, in G60S-mice, 100% of mice had at least 5% lung tumor burden, with more than half of them having greater than 20% lung burden (Figure 4e ). This resulted in an average of 30-40% lung tumor burden for both groups (Figure 4f ). Together, these results suggest that Cx43 G60S mutant mice have more numerous macroscopic and microscopic lung tumors than their control counterparts.
Cx43 mutant mice have increased metastasis to the lung To confirm that the lung tumors observed were truly metastases from the mammary gland, lung paraffinembedded sections were immunolabeled with mammaglobin, a glycoprotein which is expressed in cells derived from the mammary gland (Yang and Nonaka, 2010) .
Cx43 inhibits mammary gland tumor metastasis to the lung I Plante et al As expected, no mammaglobin was detected in normal lung tissues (Figures 5a and c) . In both spontaneous WT-ErbB2 and G60S-ErbB2 mice, over 62% of lung tumors stained positively for mammaglobin, confirming that they were from mammary gland origin (Figure 5b ). In oil-or DMBA-treated mice, 67-88% of all tumors were stained positively for mammaglobin in all groups, except oil-treated WT-FVB (no tumors found) and G60S-ErbB2 (no positive staining in six tumors analyzed) (Figures 5c and d) . Together, these results suggest that G60S mice are more prone to mammary gland tumor metastases to the lung.
Discussion
The connexin family of gap junction proteins is essential for cell proliferation, differentiation and tissue homeostasis (Herve et al., 2007) . Recent evidence has challenged the paradigm that connexins are tumor suppressors, and further suggests that connexins may even facilitate late stage disease progression and metastasis (Naus and Laird, 2010) . Thus, connexins may in fact best be considered as conditional tumor suppressors (Naus and Laird, 2010) . Although connexins seem to be linked to tumorigenesis in the breast (Lee et al., 1991 (Lee et al., , 1992 Laird et al., 1999; Kanczuga-Koda et al., 2006; McLachlan et al., 2007) , the current understanding of how these molecules are linked to cancer is relatively limited, as few studies have systematically examined the role of connexins in both early and late stages of disease progression in a unified model. We chose to assess the importance of Cx43 in breast cancer onset and progression using a mouse model that harbors an autosomal-dominant mutation in the gene encoding Cx43. As this loss-of-function mutation in a conditional tumor suppressor may not in itself be sufficient to initiate tumorigenesis and because Cx43 is also found in more than 35 cell types (Laird, 2006) , we chose to focus our analysis on the mammary gland by using the ErbB2 oncogene overexpressing mice under a mammary gland specific promoter. Not only did this new model circumvent limitations associated with in vitro and mouse xenograft models for studying the molecular mechanisms of breast cancer onset and progression, but it also allowed us to examine the 'natural tumor suppressor' role of Cx43-rich myoepithelial cells Gudjonsson et al., 2005 ). An added advantage of this model was the fact that both ErbB2 overexpression and DMBA are known to induce metastasis to the lung, which facilitated our interest in determining whether the functional status of Cx43 would impact positively or negatively on late stage disease progression and metastasis. Finally, this animal model was designed to examine the potential cross-talk mechanisms between the Cx43-rich myoepithelium and the ErbB2-positive luminal cell microenvironments as related to tumorigenesis.
Our study produced two major and somewhat unexpected key findings. First, low levels of Cx43 in the mammary gland resulted in a decreased frequency of Cx43 inhibits mammary gland tumor metastasis to the lung I Plante et al palpable mammary gland tumors, as mice harboring the G60S mutant typically exhibited a hyperplasic mammary gland. Second, G60S mutant mice were far more prone to forming lung metastases. Together, our results suggest that a reduced complement of functional Cx43 renders mice more susceptible to hyperplasic mammary glands and that functional Cx43 is protective against lung metastases. Figure 4 Cx43 mutant mice have considerable lung tumor burden, which is further increased by DMBA treatment. Haematoxylin and eosin staining revealed that lung tissue from WT-ErbB2 and G60S-ErbB2 mice was generally normal (a), with occasional areas harboring solid tumors (a, inserts). Similarly, lung tissue from oil-treated mouse cohorts was typically normal (d). In DMBA-treated mice, solid tumors were observed for all mouse groups, but were more frequently found in G60S mutant mice (d). Bars ¼ 150 mm. For all mice, 10 random histological fields were imaged and the area of abnormal tissue versus normal tissue was blindly evaluated using ImageJ software. (b, e) Graphs represent the percentage of mice with o5%, 5-20%, 20-50% or X50% of the total lung area occupied by abnormal tissue. (c, f) Graphs represent the percent mean tumor burden per total tissue area for each group±s.e.m. **Po0.01; ***Po0.001. For each group, NX6.
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Low levels of Cx43 result in delayed onset of palpable tumors In mice overexpressing ErbB2 under the control of an MMTV promoter (Guy et al., 1992) , 50% of the mice developed spontaneous mammary gland tumors at B30 weeks, and B70% of tumor-bearing mice that live over 8 months exhibit lung metastasis (Guy et al., 1992) . In our hands, 50% of WT-ErbB2 mice developed spontaneous palpable mammary gland tumors by B72 weeks of age, twice the time of the parental strain. A possible explanation for this delay in tumor onset may come from the fact that the parental strain is homozygous, having two copies of the NeuI rat gene, whereas our mice were heterozygous for ErbB2. However, a comparable cross-breeding approach between the same ErbB2-expressing mice and MMTV/Rassf3 transgenic mice resulted in similar tumor onset latency as that found in the homozygous ErbB2 mice, suggesting that this is not a sufficient explanation (Jacquemart et al., 2009 ). Another possibility is that this disparity may result from differences in mouse strains used. Although both FVB/ N-Tg(MMTVneu)202Mul/J and MMTV/Rassf3 transgenic mice were on the same FVB background, G60S mice are on a mixed background of C3 and the more tumor resistant strain, C57BL/6J (Rowse et al., 1998; Flenniken et al., 2005) . Consistently, a cross-breeding study between ErbB2 mice on the FVB mouse background and ERaKO mice on the C57BL/6 strain resulted in a considerably longer latency in tumor onset (Hewitt et al., 2002) , similar to the findings in this study. To our surprise, compared with appropriated controls, the onset of palpable mammary gland tumors was delayed in Cx43 mutant mice in both spontaneous and DMBA-treated experimental sets. However, histological analysis demonstrated that the mammary glands from mutant mice were subject to hyperplasia. Hyperplasia is one of the first steps in tumorigenesis, as further disease progression to solid tumors usually occurs within a few weeks (Boggio et al., 1998; Hewitt et al., 2002; Tsubura et al., 2007; Allred and Medina, 2008) . At least two Cx43 inhibits mammary gland tumor metastasis to the lung I Plante et al possibilities could explain these results; either mutant Cx43 delays the onset of tumorigenesis, or mutant Cx43 inhibits hyperplasic cells from proceeding to solid tumors while resident in the mammary gland. The fact that 33% of oil-treated G60S-FVB mutant mice (compared with 0% of WT-FVB) exhibit hyperplasia by week 42 suggests that Cx43 mutant mice may actually be more prone to breast tumor initiation. However, the answer was not as clear when we compared G60S-ErbB2 and WT-ErbB2 mice, as 44 and 29% of these mice, (respectively), exhibited hyperplasia in the oil-treated group at 42 weeks, and 75% of mice harboring G60S-ErbB2 spontaneously became hyperplasic at week 50. Together, this suggests that Cx43 may only have a minimal effect on inhibiting the initial stages of tumorigenesis. Instead, it is more likely that mutant Cx43 is linked to inhibiting cells from forming solid tumors while resident in the mammary gland. Similar to human breast cancer, mouse mammary gland tumorigenesis is a multistep process involving epithelial hyperproliferation (hyperplasia), progression into in situ carcinoma, invasion and metastasis (Boggio et al., 1998; Tsubura et al., 2007; Allred and Medina, 2008) . The major criteria to discriminate between in situ and invasive carcinoma is the presence of an intact myoepithelial layer and basement membrane, suggesting that myoepithelial cells can have a 'fence' role to inhibit invasiveness.
Myoepithelial cell tumor-suppressive properties
Recently we showed that reduced GJIC in myoepithelial cells of Gja1 Jrt/ þ (G60S) mice results in a delay in mammary gland ductal development during puberty, suggesting a regulatory role of Cx43 (Plante and Laird, 2008) . Similarly, it has been shown that interactions between myoepithelial and luminal cells are required for proper differentiation of luminal cells in vitro, and that this process is dependent on gap junctions (Talhouk et al., 2008) . Lately, myoepithelial cells have received more attention as they have been suggested to be a 'natural tumor suppressor' by inhibiting various neoplastic events, including cell growth, invasion and angiogenesis Barsky and Karlin, 2005; Gudjonsson et al., 2005) . In keeping with this concept, our results suggest that a full complement of Cx43 may be necessary to protect against tumor or hyperplasic cells from entering the stroma and eventually into the vasculature. Cx43 could be necessary for the proper differentiation of the myoepithelial layer. Less-differentiated myoepithelial cells would be expected to have altered expression of tumor suppressive molecules, such as maspin and TIMP-1, thereby facilitating luminal cell migration Barsky and Karlin, 2005) . Alternatively, Cx43 may be necessary to physically strengthen the epithelium barrier as we already know that Cx43 is critical to synchronous myoepithelial cell contraction (Plante and Laird, 2008) . It is also possible that decreased levels of Cx43 in the myoepithelium interfere with other adhesion mechanisms or complexes present at the plasma membrane (Laird, 2006) . However, our previous study suggests that a low level of Cx43 is sufficient to maintain the proper localization of protein constituents of tight and adherens junctions (Plante et al., 2010) . Finally, this study does not allow us to conclude whether the effects observed are due to deceased levels of Cx43, or to a decrease in GJIC, as the G60S mutant is functionally dead and also has a dominant-negative effect on coexpressed wild-type Cx43 (Flenniken et al., 2005) . Additional studies would be necessary to further dissect the full contribution of Cx43 to the myoepithelial cell layer.
Cx43 suppresses mammary gland metastasis to lung An intriguing finding from our study using this unifying model of breast tumor onset and disease progression was the fact that Cx43 protects against mammary tumor cell metastases to the lung. Confirmation that we were indeed assessing lung metastases and not serendipitous primary lung tumor formation was provided by positive identification of the tumors as being of mammary origin via the expression of mammaglobin. Given that it is known that not all mammary cell-derived tumors express mammaglobin (Yang and Nonaka, 2010) , it is likely that we are even underestimating the number of tumors of mammary origin. Furthermore, it has previously been demonstrated that ErbB2-expressing mice are known to be prone to mammary gland tumor metastases to the lung (Guy et al., 1992) .
As Cx43 mutant mice exhibit hyperplasic glands without much evidence for the presence of solid tumors in the mammary gland, we were somewhat surprised to observe a greater prevalence of metastatic lesions in the lungs. Moreover, the fact that only one G60S-ErbB2 mouse in the spontaneous experiment and less than 40% of the mutant mice in the DMBA experiment developed a palpable tumor but all mice showed metastatic lung tumors, suggests that lung seeding happened before a palpable tumor could be detected. Although not particularly common in the clinical setting, it has been reported that metastases can be found in the absence of a detectable primary tumor, or even 5-7 years before the detection of a primary tumor (Engel et al., 2003; van de Wouw et al., 2003) . In a recent mouse mammary tumor study, tumor cells were found in both the lungs and bone marrow from two different mouse models before invasive tumor cells were ever detected in the mammary gland (Husemann et al., 2008) . Interestingly, the authors observed that the basement membrane underlying hyperplasic cells within the mammary gland seemed disrupted suggesting that the myoepithelium and basement membrane may have in fact been functioning as a natural tumor suppressor, as suggested by the current study. However, we cannot rule out the possibility that undetected invasive tumor cells were present in the mammary gland of Cx43 mutant mice and it is these cells that are metastasizing to the lungs. Furthermore, it is important to note that the 'soil' where lung tumor metastases flourish is a Cx43-enriched environment (Nagata et al., 2009) and it is possible that the metastases thrive better in an environment where Cx43
Cx43 inhibits mammary gland tumor metastasis to the lung I Plante et al function is reduced. Although it is hard to model a mechanism to support this conjecture, we can also not fully eliminate this possibility.
Although connexins do not necessarily fulfill the definition of a metastasis suppressor, it is interesting to see that in our mouse model, Cx43 seems to share several characteristics with members of the metastasis suppressor family. Metastasis suppressor genes are defined as molecules that can inhibit metastasis while having little or no effect on primary tumor growth (Bodenstine and Welch, 2008) . Since the discovery of Nm23 (non-metastatic clone 23) in the late 1980s (Steeg et al., 1988) , over 23 members of this new class of cancer-related genes have been identified to have a role at various steps of the metastasis process. Among them, expression of the breast cancer metastasis suppressor 1 (BRMS1) not only inhibits metastasis of MDA-MB-435 cells to the lungs and lymph nodes when injected in the tail vein of athymic mice, but it can also restore GJIC and increase Cx43 expression in vitro (Saunders et al., 2001) , suggesting a link between those two molecules in preventing metastasis.
In summary, this novel unifying model investigating the role of Cx43 in mammary gland tumorigenesis suggests that Cx43 in the myoepithelium minimally inhibits the initial stage of disease leading to mammary cell hyperplasia. However, Cx43 was found to be more potent at inhibiting the progression of tumorigenesis as defined by metastasis to the lung. Given that Cx43 is expressed extensively in the myoepithelial layer of the mammary gland, these results allow us to propose a working model where a full complement of Cx43 in the myoepithelium may serve to enhance the 'barrier' function of this cell layer inhibiting transformed luminal cells from invading the stroma during breast cancer progression. We propose that if the integrity of the myoepithelium is compromised by reduced levels of functional Cx43, tumor cells can more readily escape the confines of the primary site and metastasize to the lung. Although we cannot determine the transformation state of the cells that are metastasizing to the lungs, we suspect that within the heterogeneity of the hyperplasic tissue in the mammary gland some cells are fully transformed and are aggressive at metastasizing to the lung. However, this working model will need further consideration as we attempt to fully understand the role of Cx43 and myoepithelial cells in breast cancer progression.
Taken together, the findings of our study suggest that a molecular mechanism encrypted into the myoepithelium is protective against breast cancer progression. As most breast cancer related deaths are linked to metastasis, understanding the mechanisms of how Cx43 contributes to this process is critical in order to determine whether connexins are potential targets for therapeutic intervention.
Materials and methods

Animal treatment and tissue collection Heterozygote Gja1
Jrt/ þ mutant mice, carrying a G60S mutation in the Gja1 gene encoding Cx43, have a mixed genetic background of C3 and C57BL/6J (Flenniken et al., 2005) .
Gja1
Jrt/ þ male mice were cross-bred with female FVB and female FVB/N-Tg(MMTVneu)202Mul/J, purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were randomly assigned to the different experimental groups and tumor onset was evaluated every week by palpation. Mice were killed when the biggest tumor reached B1 cm 3 or when mice showed signs of critical illness. For 7, anthracene (DMBA) studies, mice were exposed to DMBA or cotton oil by gavage. A total of 5 weekly doses (1 mg per 25 g of body weight) were administrated starting at 7 weeks of age. Female mice were killed using CO 2 and O 2 and collected tissues were stored at À80 1C or fixed in 10% neutral buffered formalin and then embedded in paraffin. All experimental procedures were approved by the Animal Care Committee at the University of Western Ontario following the guidelines of the Canadian Council on Animal Care.
Histology
To perform a general histological analysis, paraffin-embedded sections (7 mm thick) were stained with haematoxylin and eosin and mounted with Cytoseal (Richard-Allan Scientific, Kalamazoo, MI, USA). General histological analysis was performed by imaging several areas with 16 Â , 10 Â and 5 Â objective lenses mounted on a Zeiss (Thornwood, NY, USA) Axioscope microscope workstation equipped with a Sony (Tokyo, Japan) PowerHAD camera and Axiovision LE imaging software (Carl Zeiss Vision). At least five different animals per experimental group were evaluated.
Evaluation of lung lesions
Once mice were killed, lungs were inflated and fixed by injecting 10% buffered formalin through the trachea. Inflated lungs were kept at 4 1C in buffered formalin for at least 48 h, and visible lesions present on the lung surface were counted. Lungs were then embedded in paraffin and processed for haematoxylin and eosin staining. For each mouse, 10 random pictures were taken with a 16 Â objective (for a total of B6 mm 2 of tissue area per mouse) and the area covered by lesions evaluated blindly using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Graphs represent the average lesion surface area (lesion area/total area evaluated), per group. A minimum of six different animals per experimental group were evaluated.
Immunocytochemistry and confocal microscopy Paraffin-embedded sections (7 mm thick) were subjected to rehydration with descending grades of ethanol baths followed by microwave antigen retrieval using Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA, USA) for 5 min. After a 20 min of cool down, sections were subjected to a second antigen retrieval step, using 10 mM Tris Base, 1 mM EDTA solution (pH 9.0) at 95 1C for 30 min, followed by 20 min of cool down. Tissues were rinsed with water and blocked with 0.1% Triton X-100 and 0.15% goat serum in phosphate-buffered saline for 60 min at room temperature. Sections were then incubated with anti-mammaglobin (Abcam, Cambridge, MA, USA; 1.0 mg/ml, cat. # ab82203). Primary antibody was visualized by incubating sections with Alexa555-conjugated donkey anti-rabbit secondary antibody (Invitrogen, Burlington, ON, Canada; 0.5 mg/ml). Hoechst stain was used to visualize nuclei before mounting. Immunolabeled paraffin-embedded sections were imaged on a Zeiss LSM 510 inverted confocal microscope as previously described (Thomas et al., 2005) . At least five different animals per experimental group were evaluated.
